Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques

Virology

Volumn 358, Issue 1, 2007, Pages 69-78

  Ferrantelli, Flavia ^a,b   Buckley, Kathleen A ^a   Rasmussen, Robert A ^a,b   Chalmers, Alistair ^a   Wang, Tao ^a,b   Li, Pei Lin ^a,b   Williams, Alison L ^a   Hofmann Lehmann, Regina ^a,b   Montefiori, David C ^c   Cavacini, Lisa A ^b,e   Katinger, Hermann ^f,g   Stiegler, Gabriela ^f,g   Anderson, Daniel C ^d   McClure, Harold M ^d   Ruprecht, Ruth M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^g POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH   (Austria)

Author keywords

Neutralizing monoclonal antibodies; Oral infection; Passive immunization; Pathogenic simian human immunodeficiency virus (SHIV); Post exposure prophylaxis; Rhesus macaques

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INFANT; MACACA; NEWBORN; NEWBORN INFECTION; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; TIME; VIREMIA; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; DISEASE MODELS, ANIMAL; HIV ANTIBODIES; HIV INFECTIONS; IMMUNITY, CELLULAR; IMMUNIZATION, PASSIVE; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SURVIVAL ANALYSIS; TIME FACTORS; VIRAL LOAD; VIREMIA;

MACACA; MACACA MULATTA; PRIMATES; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33845982853     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.07.056     Document Type: Article

References (44)

1. Armbruster C., Stiegler G.M., Vcelar B.A., Jager W., Michael N.L., Vetter N., and Katinger H.W. A phase I trial with two human monoclonal antibodies (hMAb2F5, 2G12) against HIV-1. AIDS 16 (2002) 227-233
2. Armbruster C., Stiegler G.M., Vcelar B.A., Jager W., Koller U., Jilch R., Ammann C.G., Pruenster M., Stoiber H., and Katinger H.W. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J. Antimicrob. Chemother. 54 (2004) 915-920
3. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., and Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6 (2000) 200-206
4. Binley J.M., Klasse P.J., Cao Y., Jones I., Markowitz M., Ho D.D., and Moore J.P. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J. Virol. 71 (1997) 2799-2809
5. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 (2004) 13232-13252
6. Brandtzaeg P. Mucosal immunity: integration between mother and the breast-fed infant. Vaccine 21 (2003) 3382-3388
7. Bures R., Gaitan A., Zhu T., Graziosi C., McGrath K.M., Tartaglia J., Caudrelier P., El Habib R., Klein M., Lazzarin A., Stablein D.M., Deers M., Corey L., Greenberg M.L., Schwartz D.H., and Montefiori D.C. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 16 (2000) 2019-2035
8. Cavacini L.A., Samore M.H., Gambertoglio J., Jackson B., Duval M., Wisnewski A., Hammer S., Koziel C., Trapnell C., and Posner M.R. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses 14 (1998) 545-550
9. Crawford J.M., Earl P.L., Moss B., Reimann K.A., Wyand M.S., Manson K.H., Bilska M., Zhou J.T., Pauza C.D., Parren P.W., Burton D.R., Sodroski J.G., Letvin N.L., and Montefiori D.C. Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J. Virol. 73 (1999) 10199-10207
10. Ferrantelli F., and Ruprecht R.M. Neutralizing antibodies against HIV-Back in the major leagues again. Curr. Opin. Immunol. 14 (2002) 495-502
11. Ferrantelli F., Hofmann-Lehmann R., Rasmussen R.A., Wang T., Xu W., Li P.L., Montefiori D.C., Cavacini L.A., Katinger H., Stiegler G., Anderson D.C., McClure H.M., and Ruprecht R.M. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 17 (2003) 301-309
12. Ferrantelli F., Kitabwalla M., Rasmussen R.A., Cao C., Chou T.C., Katinger H., Stiegler G., Cavacini L.A., Bai Y., Cotropia J., Ugen K.E., and Ruprecht R.M. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies-implications for acquired immunodeficiency syndrome vaccine. J. Infect. Dis. 189 (2004) 71-74
13. Ferrantelli F., Rasmussen R.A., Buckley K.A., Li P.L., Wang T., Montefiori D.C., Katinger H., Stiegler G., Anderson D.C., McClure H.M., and Ruprecht R.M. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J. Infect. Dis. 189 (2004) 2167-2173
14. Haynes B.F., Fleming J., St. Clair E.W., Katinger H., Stiegler G., Kunert G., Robinson J., Scearce R.M., Plonk K., Staats H.F., Ortel T.L., Liao H.X., and Alam S.M. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308 (2005) 1906-1908
15. Hezareh M., Hessell A.J., Jensen R.C., van de Winkel J.G., and Parren P.W. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75 (2001) 12161-12168
16. Hofmann-Lehmann R., Swenerton R.K., Liska V., Leutenegger C.M., Lutz H., McClure H.M., and Ruprecht R.M. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res. Hum. Retroviruses 16 (2000) 1247-1257
17. Hofmann-Lehmann R., Vlasak J., Rasmussen R.A., Smith B.A., Baba T.W., Liska V., Ferrantelli F., Montefiori D.C., McClure H.M., Anderson D.C., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Katinger H., Stiegler G., Cavacini L.A., Posner M.R., Chou T.C., Andersen J., and Ruprecht R.M. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J. Virol. 75 (2001) 7470-7480
18. Hofmann-Lehmann R., Vlasak J., Rasmussen R.A., Jiang S., Li P.L., Baba T.W., Montefiori D.C., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Katinger H., Stiegler G., Cavacini L.A., Posner M.R., and Ruprecht R.M. Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J. Med. Primatol. 31 (2002) 109-119
19. Kitabwalla M., Ferrantelli F., Wang T., Chalmers A., Katinger H., Stiegler G., Cavacini L.A., Chou T.C., and Ruprecht R.M. Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. AIDS Res. Hum. Retroviruses 19 (2003) 125-131
20. Larsson M., Jin X., Ramratnam B., Ogg G.S., Engelmayer J., Demoitie M.A., McMichael A.J., Cox W.I., Steinman R.M., Nixon D., and Bhardwaj N. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 13 (1999) 767-777
21. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., Louder M.K., Brown C.R., Sapan C.V., Frankel S.S., Lu Y., Robb M.L., Katinger H., and Birx D.L. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73 (1999) 4009-4018
22. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., and Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6 (2000) 207-210
23. Mc Cann C.M., Song R., and Ruprecht R.M. Antibodies: can they protect against HIV infection?. Curr. Drug Targets Infect. Disord. 5 (2005) 95-111
24. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., and Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67 (1993) 6642-6647
25. Nishimura Y., Igarashi T., Haigwood N.L., Sadjadpour R., Donau O.K., Buckler C., Plishka R.J., Buckler-White A., and Martin M.A. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15131-15136
26. Parker C.E., Deterding L.J., Hager-Braun C., Binley J.M., Schulke N., Katinger H., Moore J.P., and Tomer K.B. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J. Virol. 75 (2001) 10906-10911
27. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., and Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75 (2001) 8340-8347
28. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 359 (2002) 1178-1186
29. Rasmussen R.A., Hofmann-Lehmann R., Montefiori D.C., Li P.L., Liska V., Vlasak J., Baba T.W., Schmitz J.E., Kuroda M.J., Robinson H.L., McClure H.M., Lu S., Hu S.L., Rizvi T.A., and Ruprecht R.M. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J. Med. Primatol. 31 (2002) 40-60
30. Roben P., Moore J.P., Thali M., Sodroski J., Barbas III C.F., and Burton D.R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68 (1994) 4821-4828
31. Scanlan C.N., Pantophlet R., Wormald M.R., Ollmann Saphire E., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., and Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1 → 2 mannose residues on the outer face of gp120. J. Virol. 76 (2002) 7306-7321
32. Spouge J.L. Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 7581-7585
33. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., and Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17 (2001) 1757-1765
34. Stiegler G., Armbruster C., Vcelar B., Stoiber H., Kunert R., Michael N.L., Jagodzinski L.L., Ammann C., Jager W., Jacobson J., Vetter N., and Katinger H. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS 16 (2002) 2019-2025
35. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas III C.F., Burton D.R., Ho D.D., and Moore J.P. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric QD4-lgG. J. Virol. 69 (1995) 6609-6617
36. Trkola A., Purtscher M., Muster T., et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70 (1996) 1100-1108
37. Trkola A., Kuster H., Rusert P., Joos B., Fischer M., Leemann C., Manrique A., Huber M., Rehr M., Oxenius A., Weber R., Stiegler G., Vcelar B., Katinger H., Aceto L., and Gunthard H.F. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11 (2005) 615-622
38. Veazey R.S., Shattock R.J., Pope M., Kirijan J.C., Jones J., Hu Q., Ketas T., Marx P.A., Klasse P.J., Burton D.R., and Moore J.P. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9 (2003) 343-346
39. Verrier F., Nadas A., Gorny M.K., and Zolla-Pazner S. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J. Virol. 75 (2001) 9177-9186
40. Wolbank S., Kunert R., Stiegler G., and Katinger H. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J. Virol. 77 (2003) 4095-4103
41. Wolfe E.J., Cavacini L.A., Samore M.H., Posner M.R., Kozial C., Spino C., Trapnell C.B., Ketter N., Hammer S., and Gambertoglio J.G. Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1. Clin. Pharmacol. Ther. 59 (1996) 662-667
42. Xu W., Smith-Franklin B.A., Li P.L., Wood C., He J., Du Q., Bhat G.J., Kankasa C., Katinger H., Cavacini L.A., Posner M.R., Burton D.R., Chou T.C., and Ruprecht R.M. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J. Hum. Virol. 4 (2001) 55-61
43. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., and Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75 (2001) 10892-10905
44. Zwick M.B., Wang M., Poignard P., Stiegler G., Katinger H., Burton D.R., and Parren P.W. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol. 75 (2001) 12198-12208